Company Profile:

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. Hepion Pharmaceuticals, Inc. has a research partnership with Applied Pharmaceutical Innovation. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Recent News:

On November 20, 2019, the company announced that CRV431, an anti-fibrotic agent, prevented the development of liver cirrhosis in a highly aggressive, preclinical model of liver disease. CRV431 has potently reduced Fibrosis in all experimental models tested to date.

On October 3, 2019, the company announced that it has promoted three key team members with significant cyclophilin-based drug discovery and development experience to senior management positions in order to further position the Company to advance its lead candidate, CRV431.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

HEPA’s strengths can be seen in its better growth compared with its peers. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator and MACD. The RSI stands at 63.25 with positive bias. We rate Hepion Pharmaceuticals, Inc. (HEPA) a STRONG BUY.